B-cell receptor idiotype (BCR-Id) (BCR-Id)

The B-cell receptor (BCR) idiotype is a unique tumor-specific antigen composed of the variable regions of the immunoglobulin molecule expressed by a malignant B-cell clone (Levy et al., 1982, PubMed: 7040517). In B-cell lymphomas, such as follicular lymphoma, the idiotype serves as a highly specific marker because it is unique to the tumor cells and absent from normal B cells (Bendandi et al., 1999, PubMed: 10481244). This specificity allows for the development of personalized therapies, most notably idiotype vaccines like Dasiprotimut-T (BiovaxID), which are designed to elicit a host immune response against the specific tumor clone (Schuster et al., 2011, PubMed: 21900104). The biological function of the BCR on these cells involves signal transduction that can drive tumor cell survival and proliferation (Kwak et al., 1992, PubMed: 1409918). However, the therapeutic application of idiotype targeting faces challenges, including the requirement for patient-specific manufacturing and the potential for tumor escape through antigen loss or mutation (Inoges et al., 2006, PubMed: 16446471). Despite these hurdles, the idiotype remains a significant target for active and passive immunotherapy in the treatment of B-cell malignancies (Ai et al., 2015, PubMed: 25601015). Modern research also explores the use of anti-idiotype antibodies and CAR-T cells to target this receptor more effectively (Baskar et al., 2012, PubMed: 22308293). Overall, the BCR idiotype represents a pioneering model for personalized cancer immunotherapy, acting as a molecular fingerprint for the malignant clone.

Other names

IdiotypeTumor-specific idiotypeClonal B-cell receptorId-positive BCRImmunoglobulin idiotypeB-cell receptor variable region

Active immunotherapy via personalized vaccination (idiotype protein conjugated to KLH with GM-CSF adjuvant) to induce a tumor-specific T-cell and B-cell immune response; passive immunotherapy using anti-idiotype monoclonal antibodies to induce antibody-dependent cellular cytotoxicity (ADCC) or direct apoptosis.